{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:56:02Z","timestamp":1790675762786,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03510-7","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:40:27Z","timestamp":1790628027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients In-Use Stability and Safety of Repacked Delayed-Release Tablets of a Narrow Therapeutic Index Antiseizure Agent"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4457-1167","authenticated-orcid":false,"given":"Mariame A.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8872-882X","authenticated-orcid":false,"given":"Bhanu Prakash","family":"Dongala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"DeSantiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0402-825X","authenticated-orcid":false,"given":"Ziyaur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3649-3874","authenticated-orcid":false,"given":"Mansoor A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"Suppl 2","key":"3510_CR1","first-page":"43","volume":"37","author":"LJ Willmore","year":"2003","unstructured":"Willmore LJ. Divalproex and epilepsy. Psychopharmacol Bull. 2003;37(Suppl 2):43\u201353.","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"3510_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.0013-9580.2005.39804.x","volume":"46","author":"L Kernitsky","year":"2005","unstructured":"Kernitsky L, O\u2019Hara KA, Jiang P, Pellock JM. Extended-release divalproex in child and adolescent outpatients with epilepsy. Epilepsia. 2005;46(3):440\u20133.","journal-title":"Epilepsia"},{"issue":"2","key":"3510_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1468-2982.1997.1702093.x","volume":"17","author":"FM Cutrer","year":"1997","unstructured":"Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997;17(2):93\u2013100.","journal-title":"Cephalalgia"},{"key":"3510_CR4","doi-asserted-by":"crossref","unstructured":"Drugs for bipolar disorder. Med Lett Drugs Ther. 2024;66(1699):49\u201354. file:\/\/\/C:\/Users\/rahman_76\/Downloads\/TML-article-1699a.pdf.","DOI":"10.58347\/tml.2024.1699a"},{"issue":"2","key":"3510_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12555","volume":"16","author":"MBN Krishna","year":"2024","unstructured":"Krishna MBN, Seetharam JC, Mishra A, Maiti R, Mishra BR, Srinivasan A. Total valproate versus free valproate in therapeutic drug monitoring for bipolar disorder: a cross-sectional study. Asia Pac Psychiatry. 2024;16(2):e12555.","journal-title":"Asia Pac Psychiatry"},{"issue":"2","key":"3510_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/24750573.2017.1317382","volume":"27","author":"S Vay\u0131so\u011flu","year":"2017","unstructured":"Vay\u0131so\u011flu S. Treatment response to valproate in case with generalized anxiety disorder resistant to antidepressants. Psychiatry Clin Psychopharmacol. 2017;27(2):202\u20134.","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"3510_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646384","volume":"12","author":"Z Cai","year":"2021","unstructured":"Cai Z, Lim D, Liu G, Chen C, Jin L, Duan W, et al. Valproic acid-like compounds enhance and prolong the radiotherapy effect on breast cancer by activating and maintaining anti-tumor immune function. Front Immunol. 2021;12:646384.","journal-title":"Front Immunol"},{"key":"3510_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155459","volume":"126","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wu FF, Li J, Dong JB, He HY, Li XF, et al. Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression. Phytomedicine. 2024;126:155459.","journal-title":"Phytomedicine"},{"key":"3510_CR9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.11604\/pamj.2017.27.212.11383","volume":"27","author":"S Bouchal","year":"2017","unstructured":"Bouchal S, Ouali O, Belahsen MF. Exceptionally good response to sodium valproate in patients with recurrent Sydenham\u2019s chorea. Pan Afr Med J. 2017;27:212.","journal-title":"Pan Afr Med J"},{"issue":"9","key":"3510_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/ijd.14411","volume":"58","author":"M Rashid","year":"2019","unstructured":"Rashid M, Kashyap A, Undela K. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol. 2019;58(9):1014\u201322.","journal-title":"Int J Dermatol"},{"issue":"1","key":"3510_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-1211(02)00007-4","volume":"49","author":"S Dutta","year":"2002","unstructured":"Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 2002;49(1):1\u201310.","journal-title":"Epilepsy Res"},{"issue":"12","key":"3510_CR12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/jhg.2017.91","volume":"62","author":"MM Zhu","year":"2017","unstructured":"Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017;62(12):1009\u201314.","journal-title":"J Hum Genet"},{"key":"3510_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051036","author":"NA Shnayder","year":"2024","unstructured":"Shnayder NA, Grechkina VV, Trefilova VV, Kissin MY, Narodova EA, Petrova MM, et al. Ethnic aspects of valproic acid P-oxidation. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12051036.","journal-title":"Biomedicines"},{"issue":"17","key":"3510_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1212\/WNL.0000000000002611","volume":"86","author":"R Arya","year":"2016","unstructured":"Arya R, Gillespie CW, Cnaan A, Devarajan M, Clark P, Shinnar S, et al. Obesity and overweight as CAE comorbidities and differential drug response modifiers. Neurology. 2016;86(17):1613\u201321.","journal-title":"Neurology"},{"issue":"5","key":"3510_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816\u201334.","journal-title":"Br J Clin Pharmacol"},{"key":"3510_CR16","unstructured":"FDA. Depakote (divalproex sodium) delayed-release tablets: US Food and Drug Administration. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/018723s063lbl.pdf. Accessed 25 May 2026."},{"issue":"6","key":"3510_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1212\/WNL.33.6.808","volume":"33","author":"BJ Wilder","year":"1983","unstructured":"Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology. 1983;33(6):808\u201311.","journal-title":"Neurology"},{"issue":"4","key":"3510_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4088\/JCP.v60n0405","volume":"60","author":"CA Zarate","year":"1999","unstructured":"Zarate CA, Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry. 1999;60(4):232\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"3510_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/104454601750143447","volume":"11","author":"CR Good","year":"2001","unstructured":"Good CR, Feaster CS, Krecko VF. Tolerability of oral loading of divalproex sodium in child psychiatry inpatients. J Child Adolesc Psychopharmacol. 2001;11(1):53\u20137.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"3510_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/089198879500800407","volume":"8","author":"LJ Puryear","year":"1995","unstructured":"Puryear LJ, Kunik ME, Workman R. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses. J Geriatr Psychiatry Neurol. 1995;8(4):234\u20137.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"10","key":"3510_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714.","journal-title":"CNS Drugs"},{"key":"3510_CR22","unstructured":"Palmer E. Teva Recalls Seizure Drug. 2016. https:\/\/www.fiercepharma.com\/manufacturing\/teva-recalls-seizure-drug. Accessed 6 Jun 2026."},{"key":"3510_CR23","unstructured":"White ME. Anticonvulsant Drug Recall. 2017. https:\/\/www.hmpgloballearningnetwork.com\/site\/pln\/content\/anticonvulsant-drug-recall. Accessed 6 Jun 2026."},{"key":"3510_CR24","unstructured":"Tumolo J. Divalproex Sodium Extended-Release Tablets Recalled. 2019. https:\/\/www.hmpgloballearningnetwork.com\/site\/pln\/content\/divalproex-sodium-extended-release-tablets-recalled. Accessed 6 Jun 2026."},{"key":"3510_CR25","unstructured":"Tumolo J. Anticonvulsant Tablets Recalled. 2024. https:\/\/www.hmpgloballearningnetwork.com\/site\/pln\/news\/anticonvulsant-tablets-recalled-0. Accessed 6 Jun 2026."},{"key":"3510_CR26","doi-asserted-by":"crossref","unstructured":"Mohamed EM, Hassan MA, Sibhat G, Khuroo T, Rahman Z, Khan MA. Effect of patients in-use and accelerated stability conditions on quality attributes and pharmacokinetic profile of four FDA approved extended-release anti-epileptic-drug products. Int J Pharm. 2025;668:124840.","DOI":"10.1016\/j.ijpharm.2024.124840"},{"issue":"5","key":"3510_CR27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.yebeh.2004.07.007","volume":"5","author":"MC Smith","year":"2004","unstructured":"Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav. 2004;5(5):746\u201351.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"3510_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/10837450.2018.1514049","volume":"24","author":"P Khatri","year":"2019","unstructured":"Khatri P, Desai D, Minko T. On the plasticizing properties of divalproex sodium: physicochemical and spectroscopic characterization studies. Pharm Dev Technol. 2019;24(4):455\u201364.","journal-title":"Pharm Dev Technol"},{"issue":"7","key":"3510_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1211\/jpp.62.07.0004","volume":"62","author":"VK Llewelyn","year":"2010","unstructured":"Llewelyn VK, Mangan MF, Glass BD. Stability of sodium valproate tablets repackaged into dose administration aids. J Pharm Pharmacol. 2010;62(7):838\u201343.","journal-title":"J Pharm Pharmacol"},{"key":"3510_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.seizure.2015.07.007","volume":"31","author":"N Redmayne","year":"2015","unstructured":"Redmayne N, Robertson S, Kockler J, Llewelyn V, Haywood A, Glass B. Repackaged sodium valproate tablets--meeting quality and adherence to ensure seizure control. Seizure. 2015;31:108\u201311.","journal-title":"Seizure"},{"issue":"5","key":"3510_CR31","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.xphs.2018.12.022","volume":"108","author":"S Dharani","year":"2019","unstructured":"Dharani S, Barakh Ali SF, Afrooz H, Bhattacharya R, Khan MA, Rahman Z. Quality and in-use stability comparison of brand and generics of extended-release phenytoin sodium capsules. J Pharm Sci. 2019;108(5):1808\u201317.","journal-title":"J Pharm Sci"},{"key":"3510_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121923","volume":"623","author":"S Dharani","year":"2022","unstructured":"Dharani S, Mohamed EM, Khuroo T, Ali HI, Reddy IK, Rahman Z, et al. In-use stability assessment of FDA approved metformin immediate release and extended release products for N-Nitrosodimethylamine and dissolution quality attributes. Int J Pharm. 2022;623:121923.","journal-title":"Int J Pharm"},{"issue":"1","key":"3510_CR33","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02724-3","volume":"25","author":"S Dharani","year":"2024","unstructured":"Dharani S, Mohamed EM, Rahman Z, Khan MA. Patient in-use stability testing of FDA-approved metformin combination products for N-Nitrosamine impurity. AAPS PharmSciTech. 2024;25(1):19.","journal-title":"AAPS PharmSciTech"},{"issue":"12","key":"3510_CR34","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1002\/jps.24657","volume":"104","author":"A Nguyenpho","year":"2015","unstructured":"Nguyenpho A, Ciavarella AB, Siddiqui A, Rahman Z, Akhtar S, Hunt R, et al. Evaluation of in-use stability of anticoagulant drug products: warfarin sodium. J Pharm Sci. 2015;104(12):4232\u201340.","journal-title":"J Pharm Sci"},{"key":"3510_CR35","unstructured":"ICH Q1A(R2) Guideline. Stability Testing of New Drug Substances and Products. https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf. Accessed 8 Jun 2026."},{"key":"3510_CR36","unstructured":"FDA: Depakote (divalproex sodium) Tablets. US Food and Drug Administration. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018723s037lbl.pdf."},{"key":"3510_CR37","unstructured":"MHRA. Full pack dispensing of valproate-containing medicine 2023 [Available from: https:\/\/www.gov.uk\/government\/publications\/full-pack-dispensing-of-valproate-containing-medicines\/full-pack-dispensing-of-valproate-containing-medicines. Accessed 8 Jun 2026."},{"issue":"8","key":"3510_CR38","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1007\/s00415-024-12436-8","volume":"271","author":"H Angus-Leppan","year":"2024","unstructured":"Angus-Leppan H, Arkell R, Watkins L, Heaney D, Cooper P, Shankar R. New valproate regulations, informed choice and seizure risk. J Neurol. 2024;271(8):5671\u201386.","journal-title":"J Neurol"},{"issue":"9","key":"3510_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1080\/03639045.2021.1994991","volume":"47","author":"H Chavda","year":"2021","unstructured":"Chavda H. In-use stability studies: guidelines and challenges. Drug Dev Ind Pharm. 2021;47(9):1373\u201391.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"3510_CR40","first-page":"369","volume":"13","author":"L Kassaye","year":"2013","unstructured":"Kassaye L, Genete G. Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules. Afr Health Sci. 2013;13(2):369\u201375.","journal-title":"Afr Health Sci"},{"issue":"1","key":"3510_CR41","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.xphs.2024.10.024","volume":"114","author":"K Chatterjee","year":"2025","unstructured":"Chatterjee K, Punia A, Confer AM, Lamm MS. Understanding the effect of plasticizers in film coat materials on the physical stability of amorphous solid dispersions. J Pharm Sci. 2025;114(1):468\u201376.","journal-title":"J Pharm Sci"},{"issue":"10","key":"3510_CR42","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1002\/jps.24544","volume":"104","author":"S Yassin","year":"2015","unstructured":"Yassin S, Goodwin DJ, Anderson A, Sibik J, Wilson DI, Gladden LF, et al. The disintegration process in microcrystalline cellulose based tablets, part 1: influence of temperature, porosity and superdisintegrants. J Pharm Sci. 2015;104(10):3440\u201350.","journal-title":"J Pharm Sci"},{"key":"3510_CR43","unstructured":"Namdeo Tukaram B, Vidaya Rajagopalan I, Sushi Ikumar Shartchandra P. The effects of lactose, microcrystalline cellulose and dicalcium phosphate on swelling and erosion of compressed HPMC matrix tablets: texture analyzer. Iran J Pharm Res. 2010;9(4):349\u201358."},{"key":"3510_CR44","doi-asserted-by":"crossref","unstructured":"Moussaa E, F S, Flamenta MP, Benzinea Y, Penzb F, Siepmanna J, et al. Controlled release tablets based on HPMC:lactose blends. J Drug Deliv Sci Technol: Elsevier; 2019. p. 607\u201317.","DOI":"10.1016\/j.jddst.2019.05.028"},{"key":"3510_CR45","doi-asserted-by":"crossref","unstructured":"Medarevic D, Djuris J, Krkobabic M, Ibric S. Improving tableting performance of lactose monohydrate by fluid-bed melt granulation co-processing. Pharmaceutics. 2021;13(12):2165.\u00a0https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2165","DOI":"10.3390\/pharmaceutics13122165"},{"issue":"9","key":"3510_CR46","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/cmdc.200800112","volume":"3","author":"G Petrusevski","year":"2008","unstructured":"Petrusevski G, Naumov P, Jovanovski G, Bogoeva-Gaceva G, Ng SW. Solid-state forms of sodium valproate, active component of the anticonvulsant drug epilim. ChemMedChem. 2008;3(9):1377\u201386.","journal-title":"ChemMedChem"},{"key":"3510_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051442","author":"EM Mohamed","year":"2023","unstructured":"Mohamed EM, Dharani S, Nutan MTH, Cook P, Arunagiri R, Khan MA, et al. Application of sucrose acetate isobutyrate in development of co-amorphous formulations of tacrolimus for bioavailability enhancement. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15051442.","journal-title":"Pharmaceutics"},{"issue":"12","key":"3510_CR48","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1039\/D1BM00104C","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang J, Liu Z, Wu H, Cai T. Effect of polymeric excipients on nucleation and crystal growth kinetics of amorphous fluconazole. Biomater Sci. 2021;9(12):4308\u201316.","journal-title":"Biomater Sci"},{"key":"3510_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118562","volume":"273","author":"Q Guan","year":"2021","unstructured":"Guan Q, Ma Q, Zhao Y, Jiang X, Zhang H, Liu M, et al. Cellulose derivatives as effective recrystallization inhibitor for ternary ritonavir solid dispersions: in vitro-in vivo evaluation. Carbohydr Polym. 2021;273:118562.","journal-title":"Carbohydr Polym"},{"issue":"1","key":"3510_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ijpharm.2015.08.101","volume":"495","author":"A Alhalaweh","year":"2015","unstructured":"Alhalaweh A, Alzghoul A, Mahlin D, Bergstr\u00f6m CAS. Physical stability of drugs after storage above and below the glass transition temperature: relationship to glass-forming ability. Int J Pharm. 2015;495(1):312\u20137.","journal-title":"Int J Pharm"},{"issue":"6","key":"3510_CR51","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1088\/0953-8984\/16\/6\/003","volume":"16","author":"H Liem","year":"2004","unstructured":"Liem H, Cabanillas-Gonzalez J, Etchegoin P, Bradley DDC. Glass transition temperatures of polymer thin films monitored by Raman scattering. J Phys Condens Matter. 2004;16(6):721\u20138.","journal-title":"J Phys Condens Matter"},{"key":"3510_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120034","volume":"592","author":"K B\u0113rzi\u0146\u0161","year":"2021","unstructured":"B\u0113rzi\u0146\u0161 K, Fraser-Miller SJ, Gordon KC. Recent advances in low-frequency Raman spectroscopy for pharmaceutical applications. Int J Pharm. 2021;592:120034.","journal-title":"Int J Pharm"},{"issue":"32","key":"3510_CR53","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.2174\/1381612822666160726110103","volume":"22","author":"A Erxleben","year":"2016","unstructured":"Erxleben A. Application of vibrational spectroscopy to study solid-state transformations of pharmaceuticals. Curr Pharm Des. 2016;22(32):4883\u2013911.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"3510_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ijpp\/riac001","volume":"30","author":"CX Lim","year":"2022","unstructured":"Lim CX, Aliakbari M, Gokulanathan VR, Noah S, Taskin R, Stupans I, et al. Stability implications of repackaged medications in dose administration aids: a systematic review. Int J Pharm Pract. 2022;30(2):93\u2013107.","journal-title":"Int J Pharm Pract"},{"key":"3510_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.599044","volume":"8","author":"ZY Xu","year":"2020","unstructured":"Xu ZY, Guo HL, Li L, Zhang M, Jing X, Xu ZJ, et al. Genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy. Front Pediatr. 2020;8:599044.","journal-title":"Front Pediatr"},{"key":"3510_CR56","unstructured":"FDA. Depakote (divalproex sodium) delayed-release tablets, for oral use 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/018723s068lbl.pdf. Accessed 25 May 2026."},{"issue":"17","key":"3510_CR57","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1212\/WNL.0000000000003323","volume":"87","author":"DG Vossler","year":"2016","unstructured":"Vossler DG. Antiepileptic drugs: are generics as effective as brand name? Neurology. 2016;87(17):e211\u20134.","journal-title":"Neurology"},{"issue":"12","key":"3510_CR58","first-page":"1576","volume":"26","author":"S Borghs","year":"2020","unstructured":"Borghs S, Beaty S, Parekh W, Kalilani L, Boudiaf N, Loewendorf A. Cost of epilepsy-related health care encounters in the United States. J Manag Care Spec Pharm. 2020;26(12):1576\u201381.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03510-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:04:30Z","timestamp":1790672670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03510-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3510"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03510-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors report no conflict with the reported work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"311"}}